Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective Disorder

Withdrawn before enrolling · Phase 1 · Has a placebo group

Conditions studied: Schizophrenia

In brief

This study will evaluate the safety of multiple doses of NSA-789 in subjects with schizophrenia or schizoaffective disorder. This study will also assess how NSA-789 is absorbed and eliminated, and its effect, if any, on the brain.

Key facts

Study ID

NCT00892021

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

People needed

0

Starts

2009-05-01

Expected to finish

2009-10-01

Last updated by the study team

2021-08-20

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Rockville, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.